A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial
Authors: LEITER LAWRENCE A. , CHAO JASON , SAREMI ARAMESH , DEX TERRY A. , DAVIDSON JAIME A. 
Published: June 2018

Treatments that reduce A1C levels often do not reflect improvements in both fasting and postprandial hyperglycemia. Data from 731 patients (pts) with T2D uncontrolled on basal insulin ± OADs in the LixiLan-L trial (NCT02058160) were used to investigate the association between achieving FPG/PPG targets and A1C target attainment after 30 weeks of treatment with iGlarLixi (n=366) or iGlar (n=365). Outcomes were A1C target attainment, A1C change from baseline, and mean A1C at Week 30 in pts achieving both FPG and PPG target, FPG target only, PPG target only, or neither, using ADA glycemic targets. The proportion of pts reaching PPG only, or both FPG and PPG target, was numerically higher for iGlarLixi, while the proportion reaching FPG target only was numerically higher for iGlar (Figure. 1A). iGlarLixi-treated pts reaching both FPG and PPG targets, or FPG target only, showed statistically significant greater A1C changes from baseline, lower end-of-trial A1C, and a higher proportion reaching A1C target than iGlar-treated pts (Figure. 1B-D). Despite a numerically higher proportion of pts reaching FPG target only in the iGlar arm, A1C outcomes were in favor of pts receiving iGlarLixi.
In conclusion, the complementary actions of iGlarLixi on both fasting and postprandial hyperglycemia were associated with better A1C target attainment compared with iGlar alone, which mainly targets fasting hyperglycemia.

Disclosure
L.A. Leiter: Advisory Panel; Self; AstraZeneca. Research Support; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Research Support; Self; GlaxoSmithKline plc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Research Support; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Merck & Co., Inc.. Speaker's Bureau; Self; Merck & Co., Inc.. Research Support; Self; Merck & Co., Inc.. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Advisory Panel; Self; Sanofi. Research Support; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Advisory Panel; Self; Servier. Speaker's Bureau; Self; Servier. Research Support; Self; Servier. Advisory Panel; Self; Amgen Inc.. Speaker's Bureau; Self; Amgen Inc.. Research Support; Self; Amgen Inc., Esperion Therapeutics, Kowa Pharmaceuticals America, Inc., The Medicines Company. Advisory Panel; Self; Akcea Therapeutics, Novartis Pharmaceuticals Corporation. J. Chao: None. A. Saremi: Employee; Self; Sanofi US. T.A. Dex: Employee; Self; Sanofi US. Stock/Shareholder; Self; Pfizer Inc., Merck Sharp & Dohme Corp., Teva Pharmaceutical Industries Ltd. J.A. Davidson: Other Relationship; Self; American Association of Clinical Endocrinologists. Consultant; Self; Aspire Bariatrics. Advisory Panel; Self; AstraZeneca. Consultant; Self; Boston Therapeutics, Inc.. Advisory Panel; Self; GlaxoSmithKline plc., Intarcia Therapeutics, Inc., Merck & Co., Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk A/S, Sanofi.